A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies

被引:19
作者
Jones, Curtis G. [1 ]
Pechauer, Shannon M. [2 ]
Curtis, Brian R. [3 ]
Bougie, Daniel W. [2 ]
Irani, Mehraboon S. [1 ,4 ]
Dhakal, Binod [5 ]
Pierce, Brenda [6 ]
Aster, Richard H. [2 ,5 ]
Padmanabhan, Anand [1 ,4 ]
机构
[1] BloodCtr Wisconsin, Med Sci Inst, Milwaukee, WI USA
[2] BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI USA
[3] BloodCtr Wisconsin, Platelet & Neutrophil Immunol Lab, Milwaukee, WI USA
[4] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
[5] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[6] Aurora Adv Healthcare, Div Med Oncol, Milwaukee, WI USA
基金
美国国家卫生研究院;
关键词
early diagnosis of HIT; heparin; HIT; plasma exchange; plasmapheresis; thrombocytopenia; HIT ANTIBODIES; COMPLEX;
D O I
10.1016/j.chest.2017.06.001
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Heparin-induced thrombocytopenia (HIT) is a dangerous complication of heparin therapy. HIT diagnosis is established by recognizing thrombocytopenia and/or thrombosis in an affected patient and from the results of serological tests such as the platelet factor 4 (PF4)/heparin immunoassay (PF4 ELISA) and serotonin release assay (SRA). Recent studies suggest that HIT antibodies activate platelets by recognizing PF4 in a complex with platelet glycosaminoglycans (and/or polyphosphates) and that an assay based on this principle, the PF4-dependent P-selectin expression assay (PEA), may be even more accurate than the SRA for HIT diagnosis. Here, we demonstrate that the PEA detected pathogenic antibodies before the SRA became positive in two patients with HIT studied serially, in one case even before seropositivity in the PF4 ELISA. In one of the patients treated with plasma exchange, persistent dissociation between the PEA and SRA test results was observed. These results support a role for the PEA in early HIT diagnosis.
引用
收藏
页码:E77 / E80
页数:4
相关论文
共 15 条
[1]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[2]   Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia [J].
Cines, Douglas B. ;
Yarovoi, Serge V. ;
Zaitsev, Sergei V. ;
Lebedeva, Tatiana ;
Rauova, Lubica ;
Poncz, Mortimer ;
Arepally, Gowthami M. ;
Khandelwal, Sanjay ;
Stepanova, Victoria ;
Rux, Ann H. ;
Cuker, Adam ;
Guo, Cecilia ;
Ocariza, Linnette Mae ;
Travers, Richard J. ;
Smith, Stephanie A. ;
Kim, Hugh ;
Morrissey, James H. ;
Conway, Edward M. .
BLOOD ADVANCES, 2016, 1 (01) :62-74
[3]   Management of the multiple phases of heparin-induced thrombocytopenia [J].
Cuker, Adam .
THROMBOSIS AND HAEMOSTASIS, 2016, 116 (05) :835-842
[4]  
GREINACHER A, 1994, THROMB HAEMOSTASIS, V71, P247
[5]  
KELTON JG, 1994, BLOOD, V83, P3232
[6]   Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia [J].
McKenzie, Steven E. ;
Sachais, Bruce S. .
CURRENT OPINION IN HEMATOLOGY, 2014, 21 (05) :380-387
[7]  
Padmanabhan A, 2015, THROMB HAEMOST, V114
[8]   IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia [J].
Padmanabhan, Anand ;
Jones, Curtis G. ;
Pechauer, Shannon M. ;
Curtis, Brian R. ;
Bougie, Daniel W. ;
Irani, Mehraboon S. ;
Bryant, Barbara J. ;
Alperin, Jack B. ;
Deloughery, Thomas G. ;
Mulvey, Kevin P. ;
Dhakal, Binod ;
Wen, Renren ;
Wang, Demin ;
Aster, Richard H. .
CHEST, 2017, 152 (03) :478-485
[9]   A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis [J].
Padmanabhan, Anand ;
Jones, Curtis G. ;
Curtis, Brian R. ;
Bougie, Daniel W. ;
Sullivan, Mia J. ;
Peswani, Namrata ;
McFarland, Janice G. ;
Eastwood, Daniel ;
Wang, Demin ;
Aster, Richard H. .
CHEST, 2016, 150 (03) :506-515
[10]   Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis [J].
Padmanabhan, Anand ;
Jones, Curtis G. ;
Bougie, Daniel W. ;
Curtis, Brian R. ;
McFarland, Janice G. ;
Wang, Demin ;
Aster, Richard H. .
BLOOD, 2015, 125 (01) :155-161